{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:46Z","timestamp":1761871426931,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002543","name":"Pusan National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clml.2019.10.017","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T08:38:20Z","timestamp":1572770300000},"page":"e97-e104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed\/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study"],"prefix":"10.1016","volume":"20","author":[{"given":"Ki Sun","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.10.017_bib1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.10.017_bib2","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/leu.2017.185","article-title":"Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014","volume":"31","author":"D\u2019Souza","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.10.017_bib3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2019.10.017_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.clml.2019.10.017_bib5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.seminoncol.2016.10.008","article-title":"A\u00a0look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2019.10.017_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.10.017_bib7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2783.x","article-title":"Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration","volume":"77","author":"Cibeira","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.10.017_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A\u00a0systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.10.017_bib9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of\u00a0prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.017_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.10.017_bib11","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.10.017_bib12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.10.017_bib13","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428190600821955","volume":"47","author":"Wu","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.10.017_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2008.99","article-title":"VTD combination therapy with bortezomib\u2013thalidomide\u2013dexamethasone is highly effective in advanced and refractory multiple myeloma","volume":"22","author":"Pineda-Roman","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.10.017_bib15","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.10.017_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/MO:19:4:219","article-title":"Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma","volume":"19","author":"Srkalovic","year":"2002","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2019.10.017_bib17","first-page":"133","article-title":"Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed\/refractory multiple myeloma: a prospective, multicenter, phase II study","volume":"91","author":"Offidani","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.10.017_bib18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","article-title":"Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma","volume":"129","author":"Kyriakou","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.10.017_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2141.2010.08416.x","article-title":"Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients","volume":"152","author":"Guglielmelli","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.10.017_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ajh.23394","article-title":"Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"88","author":"Kukreti","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.10.017_bib21","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.10.017_bib22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2019.10.017_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cam4.970","article-title":"Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed\/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study","volume":"6","author":"Kwon","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2019.10.017_bib24","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.leukres.2010.05.003","article-title":"The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma\u2014a report by the Polish Myeloma Study Group","volume":"34","author":"Dmoszynska","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.10.017_bib25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.017_bib26","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.017_bib27","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ejca.2010.12.026","article-title":"Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients","volume":"47","author":"Guglielmelli","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2019.10.017_bib28","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2011-04-350009","article-title":"Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma","volume":"118","author":"Madan","year":"2011","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:18Z","timestamp":1761870858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019320658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2152265019320658"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.10.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed\/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}